337 related articles for article (PubMed ID: 32998926)
1. Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate.
Poddubnyy D; Hammel L; Heyne M; Veit J; Jentzsch C; Baraliakos X
BMJ Open; 2020 Sep; 10(9):e039059. PubMed ID: 32998926
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).
Sieper J; van der Heijde D; Dougados M; Mease PJ; Maksymowych WP; Brown MA; Arora V; Pangan AL
Ann Rheum Dis; 2013 Jun; 72(6):815-22. PubMed ID: 22772328
[TBL] [Abstract][Full Text] [Related]
3. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
van der Heijde D; Cheng-Chung Wei J; Dougados M; Mease P; Deodhar A; Maksymowych WP; Van den Bosch F; Sieper J; Tomita T; Landewé R; Zhao F; Krishnan E; Adams DH; Pangallo B; Carlier H;
Lancet; 2018 Dec; 392(10163):2441-2451. PubMed ID: 30360964
[TBL] [Abstract][Full Text] [Related]
4. Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study.
Xue Y; Hu J; Liu D; Li J; Wu H; Tan C; Dai L; Sun L; Li Z; Xiao Z; Huang C; Yan Y; Ji F; Chen R; Zou H
BioDrugs; 2024 Jan; 38(1):145-156. PubMed ID: 37737952
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of tofacitinib in reduction of inflammation detected on MRI in patients with Psoriatic ArthritiS presenTing with axial involvement (PASTOR): protocol of a randomised, double-blind, placebo-controlled, multicentre trial.
Proft F; Torgutalp M; Muche B; Rios Rodriguez V; Verba M; Poddubnyy D
BMJ Open; 2021 Nov; 11(11):e048647. PubMed ID: 34785545
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
Dougados M; Wei JC; Landewé R; Sieper J; Baraliakos X; Van den Bosch F; Maksymowych WP; Ermann J; Walsh JA; Tomita T; Deodhar A; van der Heijde D; Li X; Zhao F; Bertram CC; Gallo G; Carlier H; Gensler LS;
Ann Rheum Dis; 2020 Feb; 79(2):176-185. PubMed ID: 31685553
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L;
Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593
[TBL] [Abstract][Full Text] [Related]
9. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
Deodhar A; van der Heijde D; Gensler LS; Kim TH; Maksymowych WP; Østergaard M; Poddubnyy D; Marzo-Ortega H; Bessette L; Tomita T; Leung A; Hojnik M; Gallo G; Li X; Adams D; Carlier H; Sieper J;
Lancet; 2020 Jan; 395(10217):53-64. PubMed ID: 31813637
[TBL] [Abstract][Full Text] [Related]
10. Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies.
Kiltz U; Wei JC; van der Heijde D; van den Bosch F; Walsh JA; Boonen A; Gensler LS; Hunter T; Carlier H; Dong Y; Li X; Bolce R; Strand V; Braun J
J Rheumatol; 2021 Feb; 48(2):188-197. PubMed ID: 32669450
[TBL] [Abstract][Full Text] [Related]
11. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS).
Baraliakos X; Østergaard M; Gensler LS; Poddubnyy D; Lee EY; Kiltz U; Martin R; Sawata H; Readie A; Porter B;
Clin Drug Investig; 2020 Mar; 40(3):269-278. PubMed ID: 31983056
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial.
Molto A; López-Medina C; Van den Bosch FE; Boonen A; Webers C; Dernis E; van Gaalen FA; Soubrier M; Claudepierre P; Baillet A; Starmans-Kool M; Spoorenberg A; Jacques P; Carron P; Joos R; Lenaerts J; Gossec L; Pouplin S; Ruyssen-Witrand A; Sparsa L; van Tubergen A; van der Heijde D; Dougados M
Ann Rheum Dis; 2021 Nov; 80(11):1436-1444. PubMed ID: 33958325
[TBL] [Abstract][Full Text] [Related]
14. Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study.
Deodhar A; Blanco R; Dokoupilová E; Hall S; Kameda H; Kivitz AJ; Poddubnyy D; van de Sande M; Wiksten AS; Porter BO; Richards HB; Haemmerle S; Braun J
Arthritis Rheumatol; 2021 Jan; 73(1):110-120. PubMed ID: 32770640
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
van der Heijde D; Deodhar A; Baraliakos X; Brown MA; Dobashi H; Dougados M; Elewaut D; Ellis AM; Fleurinck C; Gaffney K; Gensler LS; Haroon N; Magrey M; Maksymowych WP; Marten A; Massow U; Oortgiesen M; Poddubnyy D; Rudwaleit M; Shepherd-Smith J; Tomita T; Van den Bosch F; Vaux T; Xu H
Ann Rheum Dis; 2023 Apr; 82(4):515-526. PubMed ID: 36649967
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study.
Baraliakos X; van der Heijde D; Sieper J; Inman RD; Kameda H; Li Y; Bu X; Shmagel A; Wung P; Song IH; Deodhar A
Arthritis Res Ther; 2023 Sep; 25(1):172. PubMed ID: 37723577
[TBL] [Abstract][Full Text] [Related]
17. Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol.
Maksymowych WP; Kumke T; Auteri SE; Hoepken B; Bauer L; Rudwaleit M
Arthritis Res Ther; 2021 Oct; 23(1):274. PubMed ID: 34715908
[TBL] [Abstract][Full Text] [Related]
18. Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials.
van der Horst-Bruinsma IE; de Vlam K; Walsh JA; Bolce R; Hunter T; Sandoval D; Zhu D; Geneus V; Soriano ER; Magrey M
Adv Ther; 2022 Jun; 39(6):2806-2819. PubMed ID: 35429281
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab: in non-radiographic axial spondyloarthritis.
Burness CB; Deeks ED
Drugs; 2012 Dec; 72(18):2385-95. PubMed ID: 23231024
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis.
Mease P; Sieper J; Van den Bosch F; Rahman P; Karunaratne PM; Pangan AL
Arthritis Rheumatol; 2015 Apr; 67(4):914-23. PubMed ID: 25545240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
